Cargando…

TR-FRET-Based Immunoassay to Measure Ataxin-2 as a Target Engagement Marker in Spinocerebellar Ataxia Type 2

Spinocerebellar ataxia type 2 (SCA2) is an autosomal dominantly inherited neurodegenerative disease, which belongs to the trinucleotide repeat disease group with a CAG repeat expansion in exon 1 of the ATXN2 gene resulting in an ataxin-2 protein with an expanded polyglutamine (polyQ)-stretch. The di...

Descripción completa

Detalles Bibliográficos
Autores principales: Bux, Jessica, Sen, Nesli Ece, Klink, Isa-Maria, Hauser, Stefan, Synofzik, Matthis, Schöls, Ludger, Auburger, Georg, Riess, Olaf, Hübener-Schmid, Jeannette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10122633/
https://www.ncbi.nlm.nih.gov/pubmed/36894829
http://dx.doi.org/10.1007/s12035-023-03294-y
_version_ 1785029534275338240
author Bux, Jessica
Sen, Nesli Ece
Klink, Isa-Maria
Hauser, Stefan
Synofzik, Matthis
Schöls, Ludger
Auburger, Georg
Riess, Olaf
Hübener-Schmid, Jeannette
author_facet Bux, Jessica
Sen, Nesli Ece
Klink, Isa-Maria
Hauser, Stefan
Synofzik, Matthis
Schöls, Ludger
Auburger, Georg
Riess, Olaf
Hübener-Schmid, Jeannette
author_sort Bux, Jessica
collection PubMed
description Spinocerebellar ataxia type 2 (SCA2) is an autosomal dominantly inherited neurodegenerative disease, which belongs to the trinucleotide repeat disease group with a CAG repeat expansion in exon 1 of the ATXN2 gene resulting in an ataxin-2 protein with an expanded polyglutamine (polyQ)-stretch. The disease is late manifesting leading to early death. Today, therapeutic interventions to cure the disease or even to decelerate disease progression are not available yet. Furthermore, primary readout parameter for disease progression and therapeutic intervention studies are limited. Thus, there is an urgent need for quantifiable molecular biomarkers such as ataxin-2 becoming even more important due to numerous potential protein-lowering therapeutic intervention strategies. The aim of this study was to establish a sensitive technique to measure the amount of soluble polyQ-expanded ataxin-2 in human biofluids to evaluate ataxin-2 protein levels as prognostic and/or therapeutic biomarker in SCA2. Time-resolved fluorescence energy transfer (TR-FRET) was used to establish a polyQ-expanded ataxin-2-specific immunoassay. Two different ataxin-2 antibodies and two different polyQ-binding antibodies were validated in three different concentrations and tested in cellular and animal tissue as well as in human cell lines, comparing different buffer conditions to evaluate the best assay conditions. We established a TR-FRET-based immunoassay for soluble polyQ-expanded ataxin-2 and validated measurements in human cell lines including iPSC-derived cortical neurons. Additionally, our immunoassay was sensitive enough to monitor small ataxin-2 expression changes by siRNA or starvation treatment. We successfully established the first sensitive ataxin-2 immunoassay to measure specifically soluble polyQ-expanded ataxin-2 in human biomaterials. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12035-023-03294-y.
format Online
Article
Text
id pubmed-10122633
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-101226332023-04-24 TR-FRET-Based Immunoassay to Measure Ataxin-2 as a Target Engagement Marker in Spinocerebellar Ataxia Type 2 Bux, Jessica Sen, Nesli Ece Klink, Isa-Maria Hauser, Stefan Synofzik, Matthis Schöls, Ludger Auburger, Georg Riess, Olaf Hübener-Schmid, Jeannette Mol Neurobiol Article Spinocerebellar ataxia type 2 (SCA2) is an autosomal dominantly inherited neurodegenerative disease, which belongs to the trinucleotide repeat disease group with a CAG repeat expansion in exon 1 of the ATXN2 gene resulting in an ataxin-2 protein with an expanded polyglutamine (polyQ)-stretch. The disease is late manifesting leading to early death. Today, therapeutic interventions to cure the disease or even to decelerate disease progression are not available yet. Furthermore, primary readout parameter for disease progression and therapeutic intervention studies are limited. Thus, there is an urgent need for quantifiable molecular biomarkers such as ataxin-2 becoming even more important due to numerous potential protein-lowering therapeutic intervention strategies. The aim of this study was to establish a sensitive technique to measure the amount of soluble polyQ-expanded ataxin-2 in human biofluids to evaluate ataxin-2 protein levels as prognostic and/or therapeutic biomarker in SCA2. Time-resolved fluorescence energy transfer (TR-FRET) was used to establish a polyQ-expanded ataxin-2-specific immunoassay. Two different ataxin-2 antibodies and two different polyQ-binding antibodies were validated in three different concentrations and tested in cellular and animal tissue as well as in human cell lines, comparing different buffer conditions to evaluate the best assay conditions. We established a TR-FRET-based immunoassay for soluble polyQ-expanded ataxin-2 and validated measurements in human cell lines including iPSC-derived cortical neurons. Additionally, our immunoassay was sensitive enough to monitor small ataxin-2 expression changes by siRNA or starvation treatment. We successfully established the first sensitive ataxin-2 immunoassay to measure specifically soluble polyQ-expanded ataxin-2 in human biomaterials. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12035-023-03294-y. Springer US 2023-03-09 2023 /pmc/articles/PMC10122633/ /pubmed/36894829 http://dx.doi.org/10.1007/s12035-023-03294-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Bux, Jessica
Sen, Nesli Ece
Klink, Isa-Maria
Hauser, Stefan
Synofzik, Matthis
Schöls, Ludger
Auburger, Georg
Riess, Olaf
Hübener-Schmid, Jeannette
TR-FRET-Based Immunoassay to Measure Ataxin-2 as a Target Engagement Marker in Spinocerebellar Ataxia Type 2
title TR-FRET-Based Immunoassay to Measure Ataxin-2 as a Target Engagement Marker in Spinocerebellar Ataxia Type 2
title_full TR-FRET-Based Immunoassay to Measure Ataxin-2 as a Target Engagement Marker in Spinocerebellar Ataxia Type 2
title_fullStr TR-FRET-Based Immunoassay to Measure Ataxin-2 as a Target Engagement Marker in Spinocerebellar Ataxia Type 2
title_full_unstemmed TR-FRET-Based Immunoassay to Measure Ataxin-2 as a Target Engagement Marker in Spinocerebellar Ataxia Type 2
title_short TR-FRET-Based Immunoassay to Measure Ataxin-2 as a Target Engagement Marker in Spinocerebellar Ataxia Type 2
title_sort tr-fret-based immunoassay to measure ataxin-2 as a target engagement marker in spinocerebellar ataxia type 2
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10122633/
https://www.ncbi.nlm.nih.gov/pubmed/36894829
http://dx.doi.org/10.1007/s12035-023-03294-y
work_keys_str_mv AT buxjessica trfretbasedimmunoassaytomeasureataxin2asatargetengagementmarkerinspinocerebellarataxiatype2
AT sennesliece trfretbasedimmunoassaytomeasureataxin2asatargetengagementmarkerinspinocerebellarataxiatype2
AT klinkisamaria trfretbasedimmunoassaytomeasureataxin2asatargetengagementmarkerinspinocerebellarataxiatype2
AT hauserstefan trfretbasedimmunoassaytomeasureataxin2asatargetengagementmarkerinspinocerebellarataxiatype2
AT synofzikmatthis trfretbasedimmunoassaytomeasureataxin2asatargetengagementmarkerinspinocerebellarataxiatype2
AT scholsludger trfretbasedimmunoassaytomeasureataxin2asatargetengagementmarkerinspinocerebellarataxiatype2
AT auburgergeorg trfretbasedimmunoassaytomeasureataxin2asatargetengagementmarkerinspinocerebellarataxiatype2
AT riessolaf trfretbasedimmunoassaytomeasureataxin2asatargetengagementmarkerinspinocerebellarataxiatype2
AT hubenerschmidjeannette trfretbasedimmunoassaytomeasureataxin2asatargetengagementmarkerinspinocerebellarataxiatype2